Achieving Efficacy and Exploring Indication Expansion for Complement Inhibitors The complement community is shifting gear, with more companies than ever targeting alternative...

Making Strides in Targeting PARP, ATR, ATM, WEE1 and POLθ AstraZeneca and Merck are at the forefront of DDR inhibitor development, focusing on next-generation PARP inhibitors...